Compare ResMed Inc. (RMD) vs Vanguard Real Estate Index Fund ETF (VNQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ResMed Inc. vs Vanguard Real Estate Index Fund ETF — how do they compare? ResMed Inc. trades at $219.5 (market cap $31.73B), while Vanguard Real Estate Index Fund ETF trades at $95.14. The key difference: ResMed Inc. pays a 1.2% dividend while Vanguard Real Estate Index Fund ETF pays none, and Vanguard Real Estate Index Fund ETF is trading nearer its 52-week high, ResMed Inc. nearer its low. Which is the better fit depends on your goals.
| RMD | VNQ | |
|---|---|---|
Market Cap | $31.73B | — |
Sector | Health | — |
52-Week High | $283.28 | $100.95 |
52-Week Low | $182.82 | $87.00 |
Enterprise Value | $31.08B | — |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.05, down 3.2% on the day, with a bearish technical signal and key support at $218. The company reported strong Q4 2026 results, beating EPS estimates at $2.95, and maintains robust profitability with a 26.94% net income margin. Revenue growth remains solid, reaching $5.15B in 2025, though weak 2027 sales guidance has pressured the stock. A dividend of $0.66 is scheduled for payment in September 2026.
Outlook is mixed: strong fundamentals and a consensus price target of $235.70 suggest upside, but bearish technicals and investor lawsuits pose near-term risks. The stock offers value with a P/E of 21.19, yet competitive and regulatory challenges require monitoring for sustained growth.
VNQ trades at $95.92, down 0.1% on the day, with technical indicators showing a bearish trend as moving averages signal selling pressure while oscillators remain neutral. The ETF faces headwinds from elevated interest rates and competition from digital infrastructure REITs, though some analysts see potential in quality REITs during market downturns. Recent institutional selling activity suggests cautious positioning among major holders.
The outlook remains challenged by interest rate sensitivity and AI-driven capital rotation away from traditional REITs. Investment opportunity exists in potential mispricing during temporary headwinds, but risks include persistent rate pressures and underperformance versus broader market indices like SPY, which returned 253.49% versus VNQ's 62.61% over 10 years.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →About Vanguard Real Estate Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Real Estate 25/50 Index, an index made up of stocks of large, mid-size, and small US companies within the real estate sector. The Advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VNQ →
